Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B62ed5821c4ed9af09a80a9c4ab4a1e3c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B62ed5821c4ed9af09a80a9c4ab4a1e3c NCIT_P378 "NCI" @default.
- B62ed5821c4ed9af09a80a9c4ab4a1e3c type Axiom @default.
- B62ed5821c4ed9af09a80a9c4ab4a1e3c annotatedProperty IAO_0000115 @default.
- B62ed5821c4ed9af09a80a9c4ab4a1e3c annotatedSource NCIT_C131175 @default.
- B62ed5821c4ed9af09a80a9c4ab4a1e3c annotatedTarget "An antibody mixture composed of six humanized, immunoglobulin G1 (IgG1) monoclonal antibodies directed against three members of the human epidermal growth factor receptor (EGFR; HER) family: EGFR (HER1; ErbB1), HER2 (ErbB2) and HER3 (ErbB3), with potential antineoplastic activity. Upon administration of anti-EGFR/HER2/HER3 monoclonal antibody mixture Sym013, the six antibodies bind to non-overlapping epitopes on EGFR, HER2 and HER3, which prevents both ligand binding and receptor activation, and induce simultaneous down-modulation of EGFR, HER2 and HER3. This inhibits the activation of HER-dependent signaling pathways and HER-dependent tumor cell proliferation. Overexpression of the HER family plays a key role in many cancers; targeting multiple HER family members simultaneously may increase therapeutic efficacy." @default.